{"id":"W4408275933","doi":"10.1038/s41591-025-03572-3","title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; National Institutes of Health; Grifols; National Cancer Institute; Gilead Sciences; Servier; Astellas Pharma; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Agios Pharmaceuticals; Swedish Orphan Biovitrum; MPN Research Foundation; Leukemia and Lymphoma Society; Alexion Pharmaceuticals; Sanofi; MorphoSys; Celgene; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Randomized controlled trial; Internal medicine; Oncology; Pharmacology; Bone marrow","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002532967,0.001644102,0.002466633,0.0004157834,0.0005141273,0.001288058,0.0009456479,0.001778479,0.005375519],"category_scores_gemma":[0.001573139,0.0006588867,0.002247767,0.0004182483,0.001051123,0.001121632,0.0003424802,0.00323425,0.0009325609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007827608,"about_ca_system_score_gemma":0.001236571,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008606685,"about_ca_topic_score_gemma":0.002124144,"domain_scores_codex":[0.99936,0.0003817089,0.00003372796,0.00008394669,0.00004456415,0.00009610932],"domain_scores_gemma":[0.9990564,0.0002620036,0.000227713,0.00007800033,0.00006189571,0.0003140127],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9672354,0.007968965,0.0005594395,0.0006582533,0.0008960307,0.00007464548,0.00007050603,0.0004403162,0.004150144,0.0001412152,0.001082738,0.01672242],"study_design_scores_gemma":[0.9512917,0.0463007,0.0009612304,0.00002617052,0.000213493,0.0000433005,0.00001451712,0.0003268012,0.0002810928,0.0001157885,0.0004144199,0.00001069635],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814589,0.007579986,0.0008870246,0.001145581,0.0006288153,0.004790979,0.001394497,0.0002339332,0.001880283],"genre_scores_gemma":[0.9811792,0.004205384,0.002069694,0.002029528,0.0005530378,0.005450337,0.00150334,0.00004133643,0.002968072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005375519,"threshold_uncertainty_score":0.01798296,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01641653940877218,"score_gpt":0.3723830453634038,"score_spread":0.3559665059546316,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}